Continuous Hemodiafiltration with a Cytokine-Adsorbing Hemofilter in @entity1 with XXXX : A Preliminary Report.

@entity1 @entity650 @entity295 @entity326 @entity1457 @entity400 @entity880
UNASSIGNED: Background/Aim: We investigated the clinical efficacy of @entity400 ( @entity400 ) with AN69ST hemofilter (AN69ST- @entity400 ) in @entity1 with @entity326 . Materials and Methods: A prospective, multicenter, single-arm study was conducted. @entity1 with @entity295 and @entity1457 defined by hyperlactemia were enrolled. The @entity1 were treated with @entity400 and in accordance with the Surviving Sepsis Campaign guidelines (SSCG). Results: Thirty-four @entity1 were enrolled. On ICU admission, the mean blood @entity650 level was 44,800    77,700 pg/ml, and the mean blood @entity880 level was 69.0    49.4 mg/dl. Both the mean blood @entity650 and @entity880 levels had significantly decreased to normal ranges after 72 h of AN69ST- @entity400 . Though the mean APACHE II score was 32.7    9.8, 28-day survival was 73.5%. Conclusion: The current study suggested that adding AN69ST- @entity400 to the treatments outlined in the SSCG might lead to good outcomes for @entity1 with @entity326 , probably via the removal of cytokines from the bloodstream.    2014 S. Karger AG, Basel.
